Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Mersana Therapeutics, Inc. (NASDAQ: MRSN).

Full DD Report for MRSN

You must become a subscriber to view this report.


Recent News from (NASDAQ: MRSN)

Mersana Therapeutics to Host Conference Call Announcing Third Quarter 2018 Financial Results and Business Updates
CAMBRIDGE, Mass., Nov. 06, 2018 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody drug conjugates (ADCs) based on its Dolaflexin® and other proprietary platforms, today a...
Source: GlobeNewswire
Date: November, 06 2018 17:00
Mersana Therapeutics to Present at Upcoming Investor Conferences
CAMBRIDGE, Mass., Aug. 30, 2018 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody drug conjugates (ADCs) based on its Dolaflexin® and other proprietary platforms, today a...
Source: GlobeNewswire
Date: August, 30 2018 16:01
New Research Coverage Highlights Live Nation Entertainment, LightPath Technologies, Synchronoss Technologies, Mallinckrodt public limited company, Capricor Therapeutics, and Mersana Therapeutics - Consolidated Revenues, Company Growth, and Expectations fo
NEW YORK, Aug. 23, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Live Nation Entertainment, Inc. (NYSE:LYV), LightPath Technologies, Inc. ...
Source: GlobeNewswire
Date: August, 23 2018 07:50
Mersana Therapeutics' (MRSN) CEO Anna Protopapas on Q2 2018 Results - Earnings Call Transcript
Mersana Therapeutics (MRSN) Q2 2018 Results Earnings Conference Call August 15, 2018 08:00 PM ET Executives Eva Jack - Chief Business Officer Anna Protopapas - CEO Tim Lowinger - Chief Scientific Officer Dave Spellman - CFO Analysts Jonathan Chang - Leerink Partners Jes...
Source: SeekingAlpha
Date: August, 15 2018 12:00
Mersana Therapeutics reports Q2 results
Mersana Therapeutics (NASDAQ: MRSN ): Q2 EPS of -$0.54 More news on: Mersana Therapeutics, Earnings news and commentary, Healthcare stocks news, Read more ...
Source: SeekingAlpha
Date: August, 14 2018 16:38

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-09-1414.0514.1314.5113.67139,682

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-136,83419,42335.1851Short
2018-12-129,96929,06734.2966Cover
2018-12-113,8417,09854.1138Short
2018-12-105,3229,91653.6708Short
2018-12-077,1218,25286.2942Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on MRSN.


About Mersana Therapeutics, Inc. (NASDAQ: MRSN)

Logo for Mersana Therapeutics, Inc. (NASDAQ: MRSN)

Not available

 

Contact Information

     

     

    Current Share Structure

       


      Recent Filings from (NASDAQ: MRSN)

      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: August, 14 2018
      Quarterly report with a continuing view of a company's financial position
      Filing Type: 10-QFiling Source: edgar
      Filing Date: August, 14 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: July, 23 2018
      Pre-effective amendment to an S-3 filing
      Filing Type: S-3/AFiling Source: edgar
      Filing Date: July, 12 2018
      Simplified registration form
      Filing Type: S-3Filing Source: edgar
      Filing Date: July, 02 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: June, 29 2018
      Additional proxy soliciting materials - definitive
      Filing Type: DEFA14AFiling Source: edgar
      Filing Date: June, 11 2018
      Quarterly report with a continuing view of a company's financial position
      Filing Type: 10-QFiling Source: edgar
      Filing Date: May, 15 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: May, 14 2018
      Official notification to shareholders of matters to be brought to a vote (Proxy)
      Filing Type: DEF 14AFiling Source: edgar
      Filing Date: April, 30 2018

       

       


      Daily Technical Chart for (NASDAQ: MRSN)

      Daily Technical Chart for (NASDAQ: MRSN)


      Stay tuned for daily updates and more on (NASDAQ: MRSN)

      It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

      More to come on (NASDAQ: MRSN)

      Do your DD and if you choose, be ready to go!


       

      The Research: All source information contained in this email is from the public sources mentioned below.

       

       
       

      Thank you

      DD Report
      @DDReports

       

       


      Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in MRSN is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of MRSN and does not buy, sell, or trade any shares of MRSN. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/